|
LCTX | Lineage Cell Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.06 |
| Leverage | 76.80% |
| Market Cap | $ 329.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -67.3m |
| Margin | -677.02% |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.